Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
23 janv. 2023 09h48 HE
|
Benitec Biopharma Inc.
HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing...
Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update
10 nov. 2022 08h00 HE
|
Benitec Biopharma Inc.
HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing...
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
16 sept. 2022 08h42 HE
|
Benitec Biopharma Inc.
HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing...
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering
12 sept. 2022 22h06 HE
|
Benitec Biopharma Inc.
HAYWARD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing...
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update
02 sept. 2022 08h00 HE
|
Benitec Biopharma Inc.
HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing...